ANAPLASTIC LARGE CELL LYMPHOMA DIAGNOSIS AND TREATMENT IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS
ALK-positive systemic anaplastic large cell lymphoma occurs mainly in children, adolescents and young adults. No optimal therapy technique has been developed yet and the recurrence rate is about 30% and does not decrease due to appliance of the up-to-date chemotherapy regimens. Complex diagnosis allows stratify patients considering the actual prognostic risk factors, such as minimal residual disease and the anti-ALK antibodies titer. The novel approaches using brentuximab vedotin and crizotinib represent the major advances in managing this type of lymphoma. This review highlights the diagnostic, prognostic factors, and evidence-based treatment approaches to managing ALK-positive anaplastic large cell lymphoma.